Medical Devices

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Hyalex Orthopaedics’ new FDA-cleared Slalom™ implant, using cartilage-mimicking tech, offers a motion-preserving alternative to joint fusion.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

A novel staple-like device from Inovedis gains expanded FDA approval, promising faster, less invasive repairs for a vast range of orthopedic injuries.

Biotech firm Northwest Biotherapeutics is opening a private clinic to speed up cancer therapy access, a strategic move to control its supply chain.

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

A new alliance between UltraGreen and LifeSignals will bring advanced wearable heart monitors to a global market, tackling rising cardiovascular disease.

The medtech giant posts Q1 growth and secures critical EU approvals for new devices, navigating post-pandemic shifts and geopolitical headwinds with strong cash flow.

With a $30M+ boost and a public market debut, Ionetix aims to scale its cyclotron tech for cancer therapy, diagnostics, and future energy solutions.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

A new app for the MyoPro robotic arm empowers patients and gives clinicians powerful data, marking a new step in connected assistive technology.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Atsena Therapeutics gets the green light for the final trial phase of a promising gene therapy, offering the first real hope for patients with X-linked retinoschisis.

A new partnership will embed sensors in spinal implants, aiming to solve high patient dissatisfaction rates and disrupt a multi-billion dollar market.

The new Future Mineral UV Defense SPF 50 promises not just protection, but clinically proven anti-aging results and post-procedure care.

A breakthrough drug for pediatric Hunter syndrome, AVLAYAH™, is now accessible via home infusion through an exclusive Orsini and Denali partnership.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.

A groundbreaking knee implant offers Hoosiers a new joint-preserving option, bridging the gap between conservative care and total knee replacement.